Q2 2024
Released Jul 30, 2024, before the open
10-Q filed Aug 5, 2024, 36 days after period end · 0000078003-24-000166
Q2 2024 · 10-Q
Revenue$13.28B$13.28B +2.1% vs Q2 2023−10.7% vs Q1 2024
Net Income$41.00M$41.00M −98.2% vs Q2 2023−98.7% vs Q1 2024
EPS Diluted$0.01$0.01 −97.6% vs Q2 2023−98.2% vs Q1 2024
Operating Cash Flowderived-$1,781,000,000N/M
Free Cash Flowderived-$2,418,000,000N/M
Margins · derived
Net margin0.3%−17.6 pt vs Q2 2023
What the release said
The release
Same quarter
| Metric | Q2 2024 | Q2 2023 | Q2 2022 | Q2 2021 |
|---|---|---|---|---|
| Revenue | $13.28B | $13.01B | $27.74B | $18.90B |
| Net Income | $41.00M | $2.33B | $9.91B | $5.56B |
| EPS Diluted | $0.01 | $0.41 | $1.73 | $0.98 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Pfizer Inc · CIK 78003 · Engraved from SEC EDGAR